切换至 "中华医学电子期刊资源库"

中华细胞与干细胞杂志(电子版) ›› 2018, Vol. 08 ›› Issue (01) : 35 -38. doi: 10.3877/cma.j.issn.2095-1221.2018.01.007

所属专题: 文献

综述

肿瘤相关间充质干细胞及其靶向治疗的研究进展
王萍1, 马予洁1, 路君1, 王庆华1, 谭建明1,()   
  1. 1. 350025 福州总医院全军器官移植研究所 福建省移植生物学重点实验室
  • 收稿日期:2017-07-10 出版日期:2018-02-01
  • 通信作者: 谭建明
  • 基金资助:
    国家自然科学基金(81703225); 福建省自然科学基金(2017J01221); 福州总医院杰出青年培育专项(2015Q03)

Research progress of tumor - associated mesenchymal stem cells and its targeted therapy

Ping Wang1, Yujie Ma1, jun Lu1, Qinghua Wang1, Jianming Tan1,()   

  1. 1. Organ Transplant Institute, Fuzhou General Hospital, Fujian Key Laboratory of Transplant Biology, Fuzhou 350025, China
  • Received:2017-07-10 Published:2018-02-01
  • Corresponding author: Jianming Tan
  • About author:
    Corresponding author:Tan Jianming, Email:
引用本文:

王萍, 马予洁, 路君, 王庆华, 谭建明. 肿瘤相关间充质干细胞及其靶向治疗的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2018, 08(01): 35-38.

Ping Wang, Yujie Ma, jun Lu, Qinghua Wang, Jianming Tan. Research progress of tumor - associated mesenchymal stem cells and its targeted therapy[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2018, 08(01): 35-38.

间充质干细胞(MSCs)存在于许多组织中,在组织出现损伤时会迁移到受伤部位进行修复。而癌症可以被看作是"永远不会愈合的伤口",在肿瘤微环境中MSCs会被持续募集成为肿瘤微环境的一部分。最近出现了一种肿瘤相关间充质干细胞(TA-MSCs),它可以激活肿瘤的发生,促进肿瘤的发展与转移。本文讨论了MSCs与TA-MSCs之间的关系;探讨对TA-MSCs的最新认识及其调节癌细胞生存、增殖、迁移与耐药能力。而且,讨论了把TA-MSCs作为癌症治疗上游或者下游的靶点或者用MSCs做载体来传递癌症因子将会发展为癌症治疗的新手段。

Mesenchymal stem cells exist in many tissues and are known to actively migrate to sites of tissue injury, where they participate in wound repair. Tumours can be considered "wounds that never heal" and, in response to cues from a tumour, MSCs are continuously recruited to and become integral components of the tumour microenvironment. Recently, it has become apparent that such tumour-associated MSCs (TA-MSCs) have an active role in tumour initiation, promotion, progression and metastasis. In this review, we discuss recent advances of association of the MSC and AT-MSC and address in our understanding of the role of TA-MSCs in regulating the survival, proliferation, migration and drug resistance of tumour cells. Moreover, we discuss therapeutic approaches that target TA-MSC upstream or downstream modulators or use MSCs as vehicles for the delivery of tumoricidal agents.

1
Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells[J]. Cell Tissue Kinet, 1970, 3(4):393-403.
2
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease[J]. Nat Rev Immunol, 2008, 8(9):726-736.
3
Shi Y, Su J, Roberts AI, et al. How mesenchymal stem cells interact with tissue immune responses[J]. Trends Immunol, 2012, 33(3):136-143.
4
Zhou BO, Yue R, Murphy MM, et al. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow[J]. Cell Stem Cell, 2014, 15(2):154-168.
5
Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus[J]. Arthritis Rheum, 2010, 62(8):2467-2475.
6
Vojtassak J, Danisovic L, Kubes M, et al. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot[J]. Neuro Endocrinol Lett, 2006, 27 Suppl 2:134-137.
7
Caplan AI, Correa D. The MSC: an injury drugstore[J]. Cell stem cell, 2011, 9(1):11-15.
8
Wang Y, Chen XD, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications[J]. Nat Immunol, 2014, 15(11):1009-1016.
9
Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth[J]. Cancer Cell, 2011, 19(2):257-272.
10
Ren G, Zhao X, Wang Y, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα[J]. Cell Stem Cell, 2012, 11(6):812-824.
11
Roodhart JM, Daenen LG, Stigter EC, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids[J]. Cancer Cell, 2011, 20(3):370-383.
12
Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging[J]. Stem Cells, 2009, 27(10):2614-2623.
13
Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas[J]. Cancer Res, 2005, 65(8):3307-3318.
14
Hoogduijn MJ, Verstegen MM, Engela AU, et al. Evidence for circulating mesenchymal stem cells in patients with organ injury[J]. Stem Cells Dev, 2014, 23(19):2328-2335.
15
Stagg J. Mesenchymal stem cells in cancer[J]. Stem Cell Rev, 2008, 4(2):119-124.
16
Jung Y, Kim JK, Shiozawa Y, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis[J]. Nat Commun, 2013, 4:1795.
17
Dwyer RM, Potter-Beirne SM, Harrington KA, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells[J]. Clin Cancer Res, 2007, 13(17):5020-5027.
18
Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood[J]. Exp Hematol, 2005, 33(11):1402-1416.
19
Waite KA, Eng C. From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family[J]. Nat Rev Genet, 2003, 4(10):763-773.
20
Mclean K, Gong Y, Choi Y, et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production[J]. J Clin Invest, 2011, 121(8):3206-3219.
21
Ren G, Liu Y, Zhao X, et al. Tumor resident mesenchymal stromal cells endow naïve stromal cells with tumor-promoting properties[J]. Oncogene, 2014, 33(30):4016-4020.
22
Lin LY, Du LM, Cao K, et al. Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities[J]. Oncogene, 2016, 35(46):6038-6042.
23
Beckermann BM, Kallifatidis G, Groth A, et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma[J]. Br J Cancer, 2008, 99(4):622-631.
24
De Boeck A, Pauwels P, Hensen K, et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling[J]. Gut, 2013, 62(4):550-560.
25
Crovello CS, Lai C, Cantley LC, et al. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2[J]. J Biol Chem, 1998, 273(41):26954-26961.
26
Mandel K, Yang Y, Schambach A, et al. Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo[J]. Stem Cells Dev, 2013, 22(23):3114-3127.
27
Hanahan D, Weinberg RA. Hallmarks of cancer: the next Generation[J]. Cell, 2011, 144(5):646-674.
28
Rosová I, Dao M, Capoccia B, et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells[J]. Stem Cells, 2008, 26(8):2173-2182.
29
Wei L, Fraser JL, Lu ZY, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats[J]. Neurobiol Dis, 2012, 46(3):635-645.
30
Chen J, Park HC, Addabbo F, et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair[J]. Kidney Int, 2008, 74(7):879-889.
31
Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs[J]. Cell Stem Cell, 2008, 3(3):301-313.
32
Bexell D, Gunnarsson S, Tormin A, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas[J]. Mol Ther, 2009, 17(1):183-190.
33
Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms[J]. Cell, 2011, 147(2):275-292.
34
Gupta GP, Massagué J. Cancer metastasis: building a framework[J]. Cell, 2006, 127(4):679-695.
35
Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature, 2001, 410(6824):50-56.
36
Zhang Y, Yang P, Sun T, et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis[J]. Nat Cell Biol, 2013, 15(3):284-294.
37
Ho IA, Yulyana Y, Sia KC, et al. Matrix metalloproteinase-1-mediated mesenchymal stem cell tumor tropism is dependent on crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis[J]. FASEB J, 2014, 28(10):4359-4368.
[1] 马敏榕, 李聪, 周勤. 宫颈癌治疗研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 497-504.
[2] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[3] 王璐, 樊杨. 子宫内膜癌相关生物标志物研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 511-516.
[4] 闫甲, 刘双池, 王政宇. 胆囊癌肿瘤标志物的研究和应用进展[J]. 中华普通外科学文献(电子版), 2023, 17(05): 391-394.
[5] 徐瑜杰, 赵国栋. 晚期胃癌治疗方法的研究进展和挑战[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 451-455.
[6] 唐英俊, 李华娟, 王赛妮, 徐旺, 刘峰, 李羲, 郝新宝, 黄华萍. 人脐带间充质干细胞治疗COPD小鼠及机制分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 476-480.
[7] 李晔, 何洁, 胡锦秀, 王金祥, 田川, 潘杭, 陈梦蝶, 赵晓娟, 叶丽, 张敏, 潘兴华. 高活性间充质干细胞干预猕猴卵巢衰老的研究[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 210-219.
[8] 龙慧玲, 林蜜, 邵婷. 三维球体间充质干细胞培养技术的研究进展及其应用[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 229-234.
[9] 刘文慧, 吴涛, 张曦. 间充质干细胞联合血小板生成素受体激动剂在异基因造血干细胞移植后血小板恢复中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 242-246.
[10] 王红敏, 谢云波, 王彦虎, 王福生. 间充质干细胞治疗新冠病毒感染的临床研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 247-256.
[11] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[12] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[13] 吴寅, 陈智琴, 高勇, 权明. Her-2阳性结直肠癌的诊治进展[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 420-425.
[14] 杨蕴钊, 周诚, 石美涵, 赵静, 白雪源. 人羊水间充质干细胞对膜性肾病大鼠的治疗作用[J]. 中华肾病研究电子杂志, 2023, 12(04): 181-186.
[15] 梁宇同, 丁旭, 马国慧, 黄艳红. 间充质干细胞在宫腔粘连治疗中的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 596-599.
阅读次数
全文


摘要